{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:00:01Z","timestamp":1791482401112,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007427","name":"MPN Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41375-022-01735-6","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T05:05:44Z","timestamp":1667019944000},"page":"370-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["An MDM2 degrader for treatment of acute leukemias"],"prefix":"10.1038","volume":"37","author":[{"given":"Bridget K.","family":"Marcellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"U\u0308mit Kaniskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Clementelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-6858","authenticated-orcid":false,"given":"Lauren","family":"Herschbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Elghaity-Beckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Arandela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6732","authenticated-orcid":false,"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-9673","authenticated-orcid":false,"given":"Alan H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","volume":"119","author":"FG Rucker","year":"2012","unstructured":"Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114\u201321.","journal-title":"Blood"},{"key":"1735_CR2","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","volume":"2","author":"BK Marcellino","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018;2:3581\u20139.","journal-title":"Blood Adv"},{"key":"1735_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3324\/haematol.2012.076729","volume":"98","author":"AH Shih","year":"2013","unstructured":"Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013;98:908\u201312.","journal-title":"Haematologica"},{"key":"1735_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","volume":"55","author":"DA Freedman","year":"1999","unstructured":"Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96\u2013107.","journal-title":"Cell Mol Life Sci"},{"key":"1735_CR5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1182\/blood.V82.9.2617.2617","volume":"82","author":"CE Bueso-Ramos","year":"1993","unstructured":"Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617\u201323.","journal-title":"Blood"},{"key":"1735_CR6","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","volume":"14","author":"S Shangary","year":"2008","unstructured":"Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14:5318\u201324.","journal-title":"Clin Cancer Res"},{"key":"1735_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","volume":"28","author":"EM Stein","year":"2022","unstructured":"Stein EM, DeAngelo DJ, Chromik J, Chatterjee M, Bauer S, Lin CC, et al. Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clin Cancer Res. 2022;28:870\u201381.","journal-title":"Clin Cancer Res"},{"key":"1735_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844\u20138.","journal-title":"Science"},{"key":"1735_CR9","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","volume":"101","author":"B Reis","year":"2016","unstructured":"Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, et al. Acute myeloid leukemia patients\u2019 clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica. 2016;101:e185\u2013188.","journal-title":"Haematologica"},{"key":"1735_CR10","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2147\/OTT.S172315","volume":"12","author":"A Khurana","year":"2019","unstructured":"Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019;12:2903\u201310.","journal-title":"Onco Targets Ther"},{"key":"1735_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale B, Cheng M, Park KS, Kaniskan HU, Xiong Y, Jin J. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21:638\u201354.","journal-title":"Nat Rev Cancer"},{"key":"1735_CR12","doi-asserted-by":"publisher","first-page":"103532","DOI":"10.1016\/j.critrevonc.2021.103532","volume":"169","author":"M Ambrosini","year":"2022","unstructured":"Ambrosini M, Fuca G, Duca M, Damian S, De Santis F, Corti F, et al. Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy? Crit Rev Oncol Hematol. 2022;169:103532.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.apsb.2020.01.003","volume":"10","author":"Y Fang","year":"2020","unstructured":"Fang Y, Liao G, Yu B. Small-molecule MDM2\/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Acta Pharm Sin B. 2020;10:1253\u201378.","journal-title":"Acta Pharm Sin B"},{"key":"1735_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","volume":"176","author":"B Wang","year":"2019","unstructured":"Wang B, Wu S, Liu J, Yang K, Xie H, Tang W. Development of selective small molecule MDM2 degraders based on nutlin. Eur J Med Chem. 2019;176:476\u201391.","journal-title":"Eur J Med Chem"},{"key":"1735_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","volume":"62","author":"Y Li","year":"2019","unstructured":"Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, et al. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. J Med Chem. 2019;62:448\u201366.","journal-title":"J Med Chem"},{"key":"1735_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu CC, Miller K, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535:252\u20137.","journal-title":"Nature"},{"key":"1735_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414\u201323.","journal-title":"Leukemia"},{"key":"1735_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cam4.799","volume":"6","author":"R Kotchetkov","year":"2017","unstructured":"Kotchetkov R, Masih-Khan E, Chu CM, Atenafu EG, Chen C, Kukreti V, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed\/refractory multiple myeloma patients. Cancer Med. 2017;6:3\u201311.","journal-title":"Cancer Med"},{"key":"1735_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0106","volume":"9","author":"C Duy","year":"2019","unstructured":"Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, et al. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Disco. 2019;9:872\u201389.","journal-title":"Cancer Disco"},{"key":"1735_CR20","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"1735_CR21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1021\/jm401753e","volume":"57","author":"D Sun","year":"2014","unstructured":"Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem. 2014;57:1454\u201372.","journal-title":"J Med Chem"},{"key":"1735_CR22","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1016\/j.bmcl.2014.06.073","volume":"24","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhu J, Liu JJ, Chen X, Mihalic J, Deignan J, et al. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett. 2014;24:3782\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"1735_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-0716-1665-9_5","volume":"2365","author":"R Casement","year":"2021","unstructured":"Casement R, Bond A, Craigon C, Ciulli A. Mechanistic and Structural Features of PROTAC Ternary Complexes. Methods Mol Biol. 2021;2365:79\u2013113.","journal-title":"Methods Mol Biol"},{"key":"1735_CR24","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1074\/jbc.C000781200","volume":"276","author":"Y Peng","year":"2001","unstructured":"Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem. 2001;276:6874\u20138.","journal-title":"J Biol Chem"},{"key":"1735_CR25","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"Q Ding","year":"2013","unstructured":"Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979\u201383.","journal-title":"J Med Chem"},{"key":"1735_CR26","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci. 2016;113:7124\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"1735_CR27","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1021\/jm5011258","volume":"57","author":"C Galdeano","year":"2014","unstructured":"Galdeano C, Gadd MS, Soares P, Scaffidi S, Van Molle I, Birced I, et al. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J Med Chem. 2014;57:8657\u201363.","journal-title":"J Med Chem"},{"key":"1735_CR28","doi-asserted-by":"crossref","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genomics Proteomics Bioinform. 2022;S1672-0229(22)00008-0.","DOI":"10.1101\/2021.06.01.446564"},{"key":"1735_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10:389\u201399.","journal-title":"Cancer Cell"},{"key":"1735_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","volume":"32","author":"R Pan","year":"2017","unstructured":"Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32:748\u201360.e746.","journal-title":"Cancer Cell"},{"key":"1735_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Disco. 2014;4:362\u201375.","journal-title":"Cancer Disco"},{"key":"1735_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1101\/gad.347872.120","volume":"35","author":"AM Klein","year":"2021","unstructured":"Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev. 2021;35:575\u2013601.","journal-title":"Genes Dev"},{"key":"1735_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2015.12.008","volume":"61","author":"M Wienken","year":"2016","unstructured":"Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, et al. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016;61:68\u201383.","journal-title":"Mol Cell"},{"key":"1735_CR34","doi-asserted-by":"publisher","first-page":"eaay2163","DOI":"10.1126\/scitranslmed.aay2163","volume":"12","author":"MY Cisse","year":"2020","unstructured":"Cisse MY, Pyrdziak S, Firmin N, Gayte L, Heuillet M, Bellvert F, et al. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Transl Med. 2020;12:eaay2163.","journal-title":"Sci Transl Med"}],"updated-by":[{"DOI":"10.1038\/s41375-023-01934-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01735-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T02:02:19Z","timestamp":1688176939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01735-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01735-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-023-01934-9","URL":"https:\/\/doi.org\/10.1038\/s41375-023-01934-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJ is a cofounder and equity shareholder in Cullgen, Inc. and a consultant for Cullgen, Inc., EpiCypher, Inc., and Accent Therapeutics, Inc. YX is a cofounder, equity shareholder and a current employee of Cullgen, Inc. JL is a current employee of Cullgen, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}